Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

BACKGROUND: Outcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve outcomes. Targeted inhibition of WEE1 with small-molecule inhibitor adavosertib (AZD1775) has emerged as a therapeutic strategy to sensitize cancer cells to...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Hayden L., Blair, Helen J., Singh, Mankaran, Moorman, Anthony V., Heidenreich, Olaf, van Delft, Frederik W., Lunec, John, Irving, Julie A. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502974/
https://www.ncbi.nlm.nih.gov/pubmed/37715172
http://dx.doi.org/10.1186/s12935-023-03057-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502974/
https://www.ncbi.nlm.nih.gov/pubmed/37715172
http://dx.doi.org/10.1186/s12935-023-03057-8

Ejemplares similares